低剂量胰高血糖素预防和治疗1型糖尿病运动相关低血糖:系统综述与荟萃分析
该系统综述与荟萃分析纳入12项研究共248例1型糖尿病青少年和成人,评估低剂量胰高血糖素对比非胰高血糖素治疗对运动诱发低血糖的疗效。结果显示低剂量胰高血糖素显著降低低血糖风险(RR 0.54;95%CI 0.35,0.84)和低于范围时间(-3.91个百分点;95%CI -6.27,1.54),但总体不良事件增加(RR 2.75;95%CI 1.07,7.08)。
要点
- 低剂量胰高血糖素可降低1型糖尿病运动相关低血糖风险及TBR。
- 使用低剂量胰高血糖素时总体不良事件风险增加,需权衡获益与风险。
- 纳入研究少且异质性大,剂量与时机仍需优化。
核心结论
- 低剂量胰高血糖素可减少1型糖尿病个体运动诱发的低血糖和低于范围时间。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase和Cochrane CENTRAL至2024年9月,纳入随机对照试验和交叉研究。
- 共纳入12项研究,涉及248例1型糖尿病青少年和成人(平均年龄36±10.5岁)。
- 采用随机效应模型估计合并治疗效果,使用Risk of Bias-2工具和GRADE框架评估方法学质量。
主要发现
- 低剂量胰高血糖素显著降低低血糖风险(风险比0.54;95%CI 0.35,0.84)。
- 低剂量胰高血糖素显著降低低于范围时间(-3.91个百分点;95%CI -6.27,1.54)。
- 敏感性分析显示低血糖和TBR的效应量略更确切。
- 总体不良事件随低剂量胰高血糖素增加(风险比2.75;95%CI 1.07,7.08)。
临床怎么用
- 对于1型糖尿病运动相关低血糖的预防和治疗,可考虑低剂量胰高血糖素以降低低血糖风险和TBR。
- 使用低剂量胰高血糖素时应关注总体不良事件增加的风险。
局限性
- 纳入研究数量少且异质性大,可能影响总体结果。
- 未来需优化不同运动类型和持续时间的胰高血糖素剂量与时机以确认真实世界有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: People with type 1 diabetes (T1D) struggle to manage exercise because of hypoglycemia risk. RESEARCH DESIGN AND METHODS: This systematic review and meta-analysis evaluated low-dose glucagon's efficacy for preventing and treating exercise-induced hypoglycemia in T1D. Medline, Embase, and Cochrane CENTRAL were searched for randomized controlled trials and crossover studies until September 2024. The analysis included T1D adolescents and adults treated with low-dose glucagon versus nonglucagon treatments. Studies with glucagon-like peptides, noninsulin combinations, or uncontrolled exercise settings were excluded. Two authors extracted the data. The methodological quality was assessed with the Risk of Bias-2 tool and Grading of Recommendations Assessment, Development and Evaluations framework. Risk of Bias 2 informed a sensitivity analysis. The meta-analysis employed a random effects model to estimate the pooled treatment effects on hypoglycemia and time below range (TBR) (glucose <3.9 mmol/L), as well as secondary outcomes and adverse effects. RESULTS: Of 6,792 records, 12 studies involving 248 individuals (mean age: 36 ± 10.5 years) met inclusion criteria. The meta-analysis showed significant reductions in hypoglycemia risk (risk ratio 0.54; 95% CI 0.35, 0.84) and TBR (-3.91 percentage points; 95% CI -6.27, 1.54) with low-dose glucagon. Sensitivity analysis yielded a slightly more confident effect size for hypoglycemia and TBR. However, overall adverse events increased with low-dose glucagon (risk ratio 2.75; 95% CI 1.07, 7.08). The included studies were few and heterogeneous, which may have influenced the overall outcomes. CONCLUSIONS: Low-dose glucagon reduces exercise-induced hypoglycemia and TBR in T1D individuals. Future research should optimize glucagon dosage and timing for various exercise types and durations to confirm real-world effectiveness.
引用
- Lundemose SB, Ranjan AG, Nørgaard O, et al. Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2025. PMID: 40834249. doi:10.2337/dc25-0702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。